Pulmonx Corporation (NASDAQ:LUNG) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Pulmonx Corporation has received an average consensus recommendation of "Moderate Buy" from nine analysts, with four recommending a hold and five a buy.
• The company's stock price objective has significantly varied, with estimates ranging from $3.00 to $16.00 among different analysts.
• Pulmonx reported a loss of ($0.38) earnings per share for the last quarter, slightly exceeding the consensus estimate, along with revenues of $23.86 million.

Pulmonx Corporation (NASDAQ:LUNG - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the nine research firms that are presently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $7.6643.

Several research analysts have recently weighed in on LUNG shares. Stifel Nicolaus cut their price target on Pulmonx from $16.00 to $5.00 and set a "buy" rating for the company in a research note on Thursday, July 31st. Wells Fargo & Company dropped their price target on Pulmonx from $6.00 to $3.00 and set an "equal weight" rating for the company in a research report on Friday, August 1st. Wall Street Zen raised shares of Pulmonx from a "sell" rating to a "hold" rating in a report on Saturday, August 30th. Lake Street Capital cut their target price on shares of Pulmonx from $12.00 to $8.00 and set a "buy" rating for the company in a research note on Thursday, July 31st. Finally, D. Boral Capital reissued a "buy" rating and set a $16.00 price objective on shares of Pulmonx in a research note on Monday, September 8th.

Hedge Funds Weigh In On Pulmonx

A number of hedge funds have recently made changes to their positions in LUNG. Deutsche Bank AG lifted its stake in Pulmonx by 4.2% in the 1st quarter. Deutsche Bank AG now owns 1,147,105 shares of the company's stock valued at $7,720,000 after buying an additional 46,116 shares in the last quarter. Parkman Healthcare Partners LLC grew its position in shares of Pulmonx by 194.4% in the 1st quarter. Parkman Healthcare Partners LLC now owns 611,875 shares of the company's stock valued at $4,118,000 after acquiring an additional 404,022 shares during the period. Bank of America Corp DE raised its position in shares of Pulmonx by 556.6% in the 2nd quarter. Bank of America Corp DE now owns 481,268 shares of the company's stock valued at $1,246,000 after buying an additional 407,971 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Pulmonx by 2.9% in the 4th quarter. Northern Trust Corp now owns 372,659 shares of the company's stock valued at $2,530,000 after purchasing an additional 10,433 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Pulmonx by 1.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 320,946 shares of the company's stock valued at $2,160,000 after purchasing an additional 5,414 shares during the last quarter. Institutional investors and hedge funds own 91.04% of the company's stock.

Pulmonx Stock Up 5.6%

Shares of NASDAQ LUNG traded up $0.09 during trading on Friday, reaching $1.69. 913,296 shares of the stock were exchanged, compared to its average volume of 451,107. The business's 50-day moving average price is $2.03 and its 200 day moving average price is $3.64. The company has a market capitalization of $68.87 million, a price-to-earnings ratio of -1.18 and a beta of 0.43. The company has a quick ratio of 4.63, a current ratio of 5.35 and a debt-to-equity ratio of 0.54. Pulmonx has a twelve month low of $1.47 and a twelve month high of $9.37.

Pulmonx (NASDAQ:LUNG - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.02. The company had revenue of $23.86 million during the quarter, compared to the consensus estimate of $23.46 million. Pulmonx had a negative net margin of 62.88% and a negative return on equity of 69.76%. Pulmonx has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Pulmonx will post -1.55 EPS for the current fiscal year.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.